200
Participants
Start Date
September 2, 2025
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
0.75% Phentolamine Ophthalmic Solution
Once daily dosing
Placebo
Once daily dosing
RECRUITING
Oculus Research, Garner
RECRUITING
Glaucoma Specialist of South Florida, Delray Beach
RECRUITING
Segal Drug Trials, Delray Beach
RECRUITING
Wyse Eyecare, Northbrook
RECRUITING
Virdi Eye Clinic, Rock Island
RECRUITING
Durrie Vision, Overland Park
RECRUITING
Kannarr Eye Care, Pittsburg
RECRUITING
Zillan Clinical Research, Houston
RECRUITING
Hoopes Vision, Draper
RECRUITING
Eye Doctors of Arizona, Phoenix
RECRUITING
Carrot Eye Center, Mesa
RECRUITING
Arizona Eye Care, Chandler
RECRUITING
MRB Eye Care Consultants, Scottsdale
RECRUITING
Wolsten and Goldberg Eye Assoc., Torrance
RECRUITING
California Eye Specialists Medical Group, Pasadena
RECRUITING
Global Research Management, Glendale
RECRUITING
Gordon Schanzlin New Vision, La Jolla
RECRUITING
NVISION Clinical Research, San Diego
RECRUITING
Scripps Poway Eyecare and Optometry, San Diego
RECRUITING
Eye Research Foundation, Newport Beach
RECRUITING
Eye Health Vision Center, South Dartmouth
RECRUITING
Northeast Eye Research Associates, Woburn
RECRUITING
West Bay Eye Assoc., Warwick
Lead Sponsor
Ocuphire Pharma, Inc.
INDUSTRY